NO20050718L - Topikal behandling av hudsykdommer - Google Patents

Topikal behandling av hudsykdommer

Info

Publication number
NO20050718L
NO20050718L NO20050718A NO20050718A NO20050718L NO 20050718 L NO20050718 L NO 20050718L NO 20050718 A NO20050718 A NO 20050718A NO 20050718 A NO20050718 A NO 20050718A NO 20050718 L NO20050718 L NO 20050718L
Authority
NO
Norway
Prior art keywords
skin diseases
topical treatment
inflammatory
treating
relates
Prior art date
Application number
NO20050718A
Other languages
English (en)
Norwegian (no)
Inventor
Hildegard Kuss
Chris Rundfeldt
Manfred Kietzmann
Joachim Hoppmann
Wolfgang Baumer
Norbert Hofgen
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of NO20050718L publication Critical patent/NO20050718L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20050718A 2002-07-11 2005-02-10 Topikal behandling av hudsykdommer NO20050718L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39522102P 2002-07-11 2002-07-11
PCT/EP2003/007514 WO2004006920A1 (en) 2002-07-11 2003-07-10 Topical treatment of skin diseases

Publications (1)

Publication Number Publication Date
NO20050718L true NO20050718L (no) 2005-04-01

Family

ID=30115840

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050718A NO20050718L (no) 2002-07-11 2005-02-10 Topikal behandling av hudsykdommer

Country Status (20)

Country Link
US (1) US20040038958A1 (pl)
EP (1) EP1531818A1 (pl)
JP (1) JP2005537262A (pl)
KR (1) KR20050021464A (pl)
CN (1) CN1681500A (pl)
AR (1) AR040647A1 (pl)
AU (1) AU2003254332B2 (pl)
BR (1) BR0312696A (pl)
CA (1) CA2492093A1 (pl)
HR (1) HRP20050133A2 (pl)
IL (1) IL166016A0 (pl)
MX (1) MXPA05000486A (pl)
NO (1) NO20050718L (pl)
NZ (1) NZ537482A (pl)
PL (1) PL375487A1 (pl)
RU (1) RU2005103608A (pl)
TW (1) TW200410690A (pl)
UA (1) UA80711C2 (pl)
WO (1) WO2004006920A1 (pl)
ZA (1) ZA200500108B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538031A (en) 2002-08-29 2007-10-26 Merck & Co Inc Indoles having anti-diabetic activity
JP4340232B2 (ja) 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド 抗糖尿病活性を有するインドール類
US7580380B2 (en) * 2003-05-28 2009-08-25 Artimi Ltd Communications systems and methods
PL1713471T3 (pl) * 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
AU2005210085B2 (en) * 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
TWI339578B (en) * 2004-10-29 2011-04-01 Mitsubishi Tanabe Pharma Corp Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
JP4961131B2 (ja) * 2004-10-29 2012-06-27 田辺三菱製薬株式会社 皮膚損傷治療剤
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
WO2007071313A2 (en) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
BRPI0706523A2 (pt) * 2006-01-13 2011-01-04 Wyeth Corp composto de fórmula i; composição farmacêutica; método de tratamento de distúrbios que estão relacionados com ou são afetados pela inibição da recaptação de norepinefrina, o receptor de 5-ht6 ou o receptor de 5-ht2a; método de tratamento de um distúrbio de aprendizado, de um distúrbio cognitivo, de um distúrbio de memória, de um distúrbio de personalidade, de um distúrbio comportamental, de um distúrbio de movimento, de um distúrbio neurodegenerativo, de abstinência de droga, de distúrbio de sono, de um distúrbio alimentar, de uma toxicidade de droga aguda, de um distúrbio cardiovascular, de uma disfunção sexual, de um distúrbio gastrintestinal, de um distúrbio genitourinário, de um distúrbio de dor, de um distúrbio nervoso ou de um distúrbio de sintoma vasomotor; método de tratamento de doença de alzheimer, de um distúrbio de deficiência da atenção, de esquizofrenia, de doença de parkinson, de discinésia tardia, de ataxia, de bradicinésia, de discinésias paroxìsmicas, de sìndrome da perna irrequieta, de tremor, de tremor essencial, de epilepsia, de apoplexia ou de trauma na cabeça; método de tratamento de doença arterial coronariana, de enfarte do miocárdio, de ataque isquêmico transitório, de angina, de fibrilação atrial, de agregação plaquetária, de risco de formação de coágulo sanguìneo, de sìndrome do intestino irritável, de constipação crÈnica, de doença do refluxo gastrintestinal, de dispepsia, de incontinência urinária por estresse ou de incontinência urinária de urgência; método de tratamento de depressão, de distúrbio compulsivo obsessivo, de tendência ao suicìdio, de distúrbio de ansiedade, de distúrbio bipolar, de distúrbio de pánico, de abstinência de nicotina, de abstinência de álcool, de abstinência de cocaìna, de abstinência de heroìna, de abstinência de anfetamina, de abstinência de drogas narcóticas, de insÈnia, de apnéia do sono, de narcolepsia, de distúrbio afetivo sanzonal, de sìndrome da perna irrequieta, de distúrbio de sono de turno de trabalho, de sìndrome da fase do sono retardada, de anorexia nervosa, de bulimia nervosa, de sìndrome do comer noturno, de superalimentação compulsiva, de sìndrome da fadiga crÈnica, de fibromialgia, de neuropatia de dor, de dor antinociceptiva, de sìndrome da dor crÈnica, de neuropatia diabética, de fogacho ou de suor noturno; e uso de um composto
AU2007218725B2 (en) 2006-02-21 2011-12-01 Eisai R & D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
US8530654B2 (en) 2007-02-16 2013-09-10 Eisai R&D Management Co., Ltd. Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid
CN101687819B (zh) 2007-08-17 2013-03-20 卫材R&D管理有限公司 外用剂
CN101687820B (zh) 2007-08-17 2012-07-25 卫材R&D管理有限公司 喹唑啉衍生物的制造方法
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
CN106795172B (zh) 2014-09-29 2020-07-28 武田药品工业株式会社 1-(1-甲基-1h-吡唑-4-基)-n-((1r,5s,7s)-9-甲基-3-氧杂-9-氮杂双环[3.3.1]壬-7-基)-1h-吲哚-3-甲酰胺的晶型
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341783A (en) * 1980-07-31 1982-07-27 Lemmon Company Topical use of dyphylline and dyphylline containing compositions
WO1994024984A2 (en) * 1993-04-30 1994-11-10 Winget Rodner R Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
DE59913617D1 (de) * 1998-04-28 2006-08-03 Elbion Ag Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.

Also Published As

Publication number Publication date
BR0312696A (pt) 2005-04-26
US20040038958A1 (en) 2004-02-26
RU2005103608A (ru) 2005-06-27
WO2004006920A1 (en) 2004-01-22
CN1681500A (zh) 2005-10-12
AU2003254332A1 (en) 2004-02-02
TW200410690A (en) 2004-07-01
AR040647A1 (es) 2005-04-13
EP1531818A1 (en) 2005-05-25
NZ537482A (en) 2006-09-29
CA2492093A1 (en) 2004-01-22
UA80711C2 (en) 2007-10-25
PL375487A1 (pl) 2005-11-28
IL166016A0 (en) 2006-01-15
MXPA05000486A (es) 2005-07-22
ZA200500108B (en) 2005-02-23
JP2005537262A (ja) 2005-12-08
KR20050021464A (ko) 2005-03-07
HRP20050133A2 (en) 2005-04-30
AU2003254332B2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EP1363632A4 (en) SELECTIVE CANNABIMIMETIC AMINOALKYLINDOLES OF A RECEPTOR
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
ATE499934T1 (de) Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
NO20060307L (no) Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet
NO20051692L (no) Anvendelse av indolylderivater for fremstilling av et medikament for behandling av allergisk rhinitt
ATE470446T1 (de) Neues verfahren und zusammensetzungen zur örtlichen behandlung von meniere-krankheit, tinnitus und/oder hörverlust
BR0312696A (pt) Tratamento tópico de doenças da pele
ATE448232T1 (de) Substituierte heterozyklen
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
NO20050569D0 (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
ECSP055844A (es) Nuevos compuestos triciclicos
DE60335083D1 (de) Derivate von alpha-phenylthiocarbon- und alpha-phenyloxycarbonsäuren, die für die behandlung von auf die aktivierung von ppar alpha ansprechende krankheiten geeignet sind
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
NO20075199L (no) Treatment or prevention of pruritus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application